Indian Journal of Cancer
Home  ICS  Feedback Subscribe Top cited articles Login 
Users Online :2892
Small font sizeDefault font sizeIncrease font size
Navigate here
Resource links
   Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
   Article in PDF (344 KB)
   Citation Manager
   Access Statistics
   Reader Comments
   Email Alert *
   Add to My List *
* Registration required (free)  

  In this article

 Article Access Statistics
    PDF Downloaded285    
    Comments [Add]    

Recommend this journal


  Table of Contents  
Year : 2011  |  Volume : 48  |  Issue : 2  |  Page : 268-269

Successful outcome of pregnancy in a case of essential thrombocytosis treated with hydroxyurea

1 Section of Internal Medicine, Emam Khomeini Hospital, Urmia, Iran
2 Urmia University of Medical Sciences, Emam Khomeini Hospital, Urmia, Iran

Date of Web Publication11-Jul-2011

Correspondence Address:
N Valizadeh
Urmia University of Medical Sciences, Emam Khomeini Hospital, Urmia
Login to access the Email id

Source of Support: None, Conflict of Interest: None

DOI: 10.4103/0019-509X.82898

Rights and Permissions

How to cite this article:
Oskuie A E, Valizadeh N. Successful outcome of pregnancy in a case of essential thrombocytosis treated with hydroxyurea. Indian J Cancer 2011;48:268-9

How to cite this URL:
Oskuie A E, Valizadeh N. Successful outcome of pregnancy in a case of essential thrombocytosis treated with hydroxyurea. Indian J Cancer [serial online] 2011 [cited 2021 Dec 1];48:268-9. Available from: https://www.indianjcancer.com/text.asp?2011/48/2/268/82898


Hydroxyurea is an oral antineoplastic agent. Hydroxyurea inhibits ribonucleotide reductase enzyme and decreases production of deoxyribonucleotides which are used for DNA synthesis and repair. [1] Hydroxyurea increases the level of fetal hemoglobin and decreases sickling of red blood cells in sickle cell disease. [2] It has an important role in the treatment of chronic myeloproliferative disorders especially in polycythemia vera and essential thrombocytosis.

In animal studies, teratogenicity and embryotoxicity of hydroxyurea have been described, but there are no adequate and well-controlled studies described in pregnant women. [3] We hereby report the outcome of pregnancy in a case of essential thrombocytosis treated with hydroxyurea. A 42-year-old woman was diagnosed with essential thrombocytosis in 2005 when she presented with a spontaneous splenic rupture and thrombocytosis (platelet count = 1300,000/μl) and underwent a splenectomy. The diagnosis of essential thrombocytosis was established based on splenomegaly, thrombocytosis, bone marrow aspiration, and trephine biopsy findings in the absence of elevated markers of inflammation and other causes of thrombocytosis. She was treated with hydroxyurea 1.5 g daily and aspirin (ASA) 80 mg daily. Her hematologist advised her on the appropriate contraceptive measures while on hydroxyurea. Hailing from a small village she did not have regular follow ups and had an unplanned pregnancy while on hydroxyurea. She followed up with her physician during the fifth month of her pregnancy. Hydroxyurea was ceased and she was referred for a specialist opinion for termination of pregnancy. The patient, however, decided to continue with the pregnancy.

On admission, laboratory findings are included: WBC = 14,500/μl, Hb = 13.9 g/dl, MCV = 99.3 fl, platelet count = 1026,000/μl. She had normal vaginal delivery and the newborn was a term 2.7 kg male baby with normal appearance and an apgar score of 8−9. In this case, of essential thrombocytosis exposure to hydroxyurea in the first and second trimester did not result in an adverse fetal outcome.

In 2001, Thauvin-Robinet et al., reported outcome of pregnancy with hydroxyurea in 31 cases (sickle cell disease, essential thrombocytosis,chronic myelogenous leukemia ( CML) and chronic myeloid splenomegaly). In their study, exposure to hydroxyurea (HU) had been occurred in first trimester of pregnancy in 22/31 patients, during first and second trimester in 2/31 patients, in third trimester in 2/31 cases and during whole pregnancy period in 3/31 of cases. In 2/31 cases, the exact period of exposure was unknown. The hydroxyurea dosage was 0.5−6 g daily. They did not see any major malformation in their case series with exposure to hydroxyurea, but they found a significant rate of intrauterine growth retardation (IUGR), fetal death, and prematurity. They concluded that exposure with hydroxyurea should never be an indication for termination of pregnancy, but they recommended a careful follow up with physical, biological and sonographic examination and fetal chromosomal analysis. [4] Fadilah et al., have reported that treatment of CML during pregnancy with hydroxyurea, which was started in 27th week of pregnancy had no adverse effect on maternal and fetal health. [5]

Although, there are reports regarding reproductive and developmental toxicity of hydroxyurea in experimental animals, [6] but only a few reports exist regarding safety of hydroxyurea in pregnant females. In this case of essential thrombocytosis, exposure to hydroxyurea during first and second trimester of pregnancy did not have teratogenic effect on the fetus. However, more cases should be studied before a definite conclusion is to be made.

We recommend appropriate contraceptive measures for females of child-bearing age on hydroxyurea. Women who have an unplanned pregnancy on hydroxyurea should stop hydroxyurea and inform their physicians in time to take decision about pregnancy termination. Hematologists should consider early chromosomal analysis of fetus and serial ultrasonography and pregnancy termination only for selected pregnancies with exposure to hydroxyurea.

  References Top

1.Hande KR. Principal and pharmacology of Chemotherapy. Text book of Wintrobe's Clinical hematology. 2 nd ed, Vol. 2. Philadelphia,USA. Lippincott Williams and Willkins; 2004. p. 1958-9.  Back to cited text no. 1
2.Butler E. Sickle cell anemia and related abnormalities. Text book of Williams Hematology. 7 th ed. Mc Graw-Hill; 2006. p. 681  Back to cited text no. 2
3.Drug information:Hydroxyurea. Feb 17, 2009.  Back to cited text no. 3
4.Thauvin-Robinet C, Maingueneau C, Robert E, Elefant E, Guy H, Caillot D, et al. Exposure to hydroxyurea during pregnancy: A case series. Leukemia 2001;15:1309-11.  Back to cited text no. 4
5.Fadilah SA, Ahmad-Zailani H, Soon-Keng C, Norlaila M. Successful treatment of CML during pregnancy with hydroxyurea. Leukemia 2002;16:1202-3.  Back to cited text no. 5
6.Liebelt EL, Balk SJ, Faber W, Fisher JW, Hughes CL, Lanzkron SM, et al. NTP-CERHR expert panel report on the reproductive and developmental toxicity of hydroxyurea. Birth Defects Res B Dev Reprod Toxicol 2007:80:259-366.  Back to cited text no. 6


Print this article  Email this article


  Site Map | What's new | Copyright and Disclaimer
  Online since 1st April '07
  2007 - Indian Journal of Cancer | Published by Wolters Kluwer - Medknow